We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 17, 2020

Pembrolizumab Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
J. Clin. Oncol 2020 May 29;[EPub Ahead of Print], CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, PK Cheema, D Rodriguez-Abreu, M Wollner, JC Yang, J Mazieres, FJ Orlandi, A Luft, M Gümüş, T Kato, GP Kalemkerian, Y Luo, V Ebiana, MC Pietanza, HR Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading